Avicanna Inc · TSX:AVCN
Avicanna — Investor Presentation (April 2024)
24 slides from Avicanna's investor presentation, Apr 1, 2024
Slide 1: An International Biopharmaceutical Strategy
Q2 2024 An International Biopharmaceutical Strategy Avicanna Is a Commercial-Stage International Biopharmaceutical Company Focused on the Advancement and Commercialization of Evidence-Based Cannabinoid-Based Products for the Global Medical and Pharmaceutical Market Segments TSX: AVCN OTCQX: AVCNF FS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations and other applicable sec
Slide 3: Corporate Highlights
0.1 Corporate Highlights An International Medical and Biopharmaceutical Strategy Commercial platform • 4 commercial stage business pillars • 30+ commercialized proprietary SKUs • First pharmaceutical marketing authorization obtained during Q1 2024 (Trunerox) • Addressing a global market opportunity
Slide 4: Avicanna's Commercial Stage Business Pillars
0.2 Avicanna’s 4 Commercial Stage Business Pillars Medical Cannabis Medical Cannabis Care Pharmaceutical Active Pharmaceutical Products Platform* Products Ingredients *MyMedi.ca is operated by Northern Green Canada for the Canadian market 04 © 2024 Avicanna Inc.
Slide 5: Timeline and Evolution
0.3 Timeline and Evolution Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform
Slide 6: Four Commercial Stage Business Pillars
1. Four Commercial Stage Business Pillars Addressing an Emerging Global Market Opportunity
Slide 7: Medical Cannabis Products and RHO Phyto
1.1 Medical Cannabis Products and RHO Phyto Advanced Drug Delivery System Formulations (CBD, THC, CBG) - for International Medical and Wellness Market Segments Transdermal Gel Oil Drops Capsules Water-Soluble Infusers Sublingual Spray Local Creams Tablets Gummies © 2024 Avicanna Inc.
Slide 8: Canadian Commercialization Infrastructure
1.1.1 Canadian Commercialization Infrastructure 27 Proprietary and Commercial SKUs Across 133 Commercial Listings National Medical Channels Provincial Retail Channels 27 7 Proprietary Commercial SKUs National Medical Cannabis Across 4 Brands Portals Offering Avicanna Products Including MyMedi.ca 79
Slide 9: MyMedi.ca
1.2 MyMedi.ca MyMedi.ca MEDICAL CANNABIS CARE
Slide 10: MyMedi.ca
1.2.1 MyMedi.ca A Complete Medical Cannabis Care Platform for Canadian Patients and the Medical Community • Evidence-driven medical cannabis formulary - with 200+ SKUs from over 35 brands • Pharmacist-led and bilingual patient support programs • Specialty care programs including compassionate pricin
Slide 11: Medical Affairs, Education and Training
1.2.2 Medical Affairs, Education and Training Health Care Providers • Training and product guidelines on dosing and titration based on the highest-level of evidence • Introduction to Cannabinoid based • Introduction to the Endocannabinoid • Educational modules and courses including: medicine System
Slide 12: Pharmaceutical Products and Pipeline
1.3 Pharmaceutical Products and Pipeline
Slide 13: Trunerox
1.3.1 TruneroxTM Marketing Authorization Obtained in Colombia by INVIMA Q1 2024 • Clinical indications: Adjunctive treatment of seizures associated with Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS) • Expected commercialization in Colombia late 2024 with opportunities to expand into other S
Slide 14: Pharmaceutical Pipeline and Drug Candidates
1.3.2 Pharmaceutical Pipeline and Drug Candidates Designed to Address 5 Major Clinical Areas Sleep Eczema/ Pain Anxiety & Epilepsy Epidermolysis Management Depression Bullosa • Candidates are in various stages of R&D, pre-clinical to real world evidence studies and or registration stage • Leveraging
Slide 15: Active Pharmaceutical Ingredients (Aureus Santa Marta)
1.4 Active Pharmaceutical Ingredients (Aureus Santa Marta™)
Slide 16: Active pharmaceutical ingredients (Aureus Santa Marta)
1.4.1 Active pharmaceutical ingredients (Aureus Santa Marta™) Avicanna’s Supply Chain Business Segment and Vertical integration • 17 international markets Raw Material Business Unit Branded as Aureus Santa Marta • Avicanna’s low cost and consistent supply of cannabinoids for its finished products th
Slide 17: Scientific Platform
2. Scientific Platform R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products
Slide 18: Established Scientific Platform
2.1 Established Scientific Platform 30+ 10+ Proprietary Scientists Commercial Products R&D through several Health 7 Canada issued Cannabis Pending Patents Research Licenses 11 Commercial Stage Canadian Government Advanced Drug Delivery Research Grants Systems Products Awarded Since 2020 018 © 2024
Slide 19: World-Class Institutional Collaborations
2.2 World-Class Institutional Collaborations 20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions since 2017 019 © 2024 Avicanna Inc.
Slide 20: Financial Overview
3. Financial Overview AVICANNA"
Slide 21: Financial & Capital Overview
3.1 Financial & Capital Overview Highlights • 2023 revenue of $16.8M, growth of 314% from $4M in 2022 • $6.67M consolidated gross profit, an increase of more than 500% from 2022 • Northern American gross margins of 45% • $92M shares issued and outstanding* Revenue to Gross Profit 2021 – 2023 $18M TSX
Slide 22: Management and Board of Directors
3.2 Management and Board of Directors Senior Management Team Board of Directors Aras Azadian Aras Azadian Founder and CEO Founder and CEO Phillip Cardella Eileen McCormack Chief Financial Officer Independant Director Stephen Kim John McVicar Chief Legal Officer & General Counsel Independant Director
Slide 23: Corporate Highlights
3.3 Corporate Highlights • De-risked investment - commercial stage, with key regulatory approvals and milestones achieved, with several product lines • Diversified - scalable and high margin revenue streams • Experienced management - proven track record since 2016 • Intellectual property powerhouse
Slide 24: Thank You
AVICANNA Thank You